Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Shares Outstanding (Weighted Average) (2019 - 2026)

Pliant Therapeutics has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $61.8 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 0.95% to $61.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $61.8 million through Mar 2026, up 0.95% year-over-year, with the annual reading at $61.4 million for FY2025, 1.37% up from the prior year.
  • Shares Outstanding (Weighted Average) was $61.8 million for Q1 2026 at Pliant Therapeutics, up from $61.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $61.8 million in Q1 2026 and troughed at $36.1 million in Q1 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $60.2 million (2024), against an average of $55.3 million.
  • Year-over-year, Shares Outstanding (Weighted Average) surged 59.42% in 2023 and then grew 0.95% in 2026.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $42.0 million in 2022, then soared by 39.75% to $58.7 million in 2023, then increased by 3.1% to $60.5 million in 2024, then increased by 1.37% to $61.4 million in 2025, then increased by 0.71% to $61.8 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Shares Outstanding (Weighted Average) are $61.8 million (Q1 2026), $61.4 million (Q4 2025), and $61.4 million (Q3 2025).